imidazolyl sodium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: imidazolyl sodium
• 英文别名: imidazolyl-sodium
• 化学式: C₃H₃N₂Na
• 分子量: 90.06
• InChiKey: ACDMHVQYOFHZJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  6.0
• 可旋转键数：
  0.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.68
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  imidazolyl sodium 、 2-<(2-甲氧基苯氧基)甲基>-3-(2-氯乙酰基)-1,3-噻唑烷 在 ice 、 水 、 乙酸乙酯 、 Sodium sulfate-III 、 crude residue 、 SiO2 作用下， 以 二甲基亚砜 为溶剂， 反应 1.0h， 以to give 3-(imidazol-1-yl)acetyl-2-(o-methoxyphenoxy)methyl-thiazolidine (5.1 g) as a colourless oil的产率得到2-咪唑-1-基-1-[2-[(2-甲氧基苯氧基)甲基]-1,3-噻唑烷-3-基]乙酮
  参考文献：
  名称：

  Antitussive and mucus regulating 2-substituted thiazolidines

  摘要：

  具有以下式子I的2-取代噻唑烷化合物：##STR1## 其中X是CH.sub.2、O或S，R是羟基或酰氧基、烷氧基、烯氧基或炔基氧基，R.sub.1是氢或式子##STR2##的基团，R.sub.2是氢或自由或酯化的羧基，R.sub.a和R.sub.b是氢或甲基，p为零或1，R.sub.3是氢、C.sub.1-C.sub.2烷基磺酰基、苯基或对氯苯基、对甲基磺酰基或酰基；可用作调节粘液、止咳和抗支气管痉挛剂。

  公开号：

  US04857643A1
• 作为试剂：
  描述：

  4-chloro-6-<2',3'-O-isopropylidene-5'-O-trityl-α-D-ribofuranosyl(chloro)methyl>pyrimidine 在 imidazolyl sodium 、 氨 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 6-[(3aR,6R,6aR)-2,2-Dimethyl-6-trityloxymethyl-dihydro-furo[3,4-d][1,3]dioxol-(4E)-ylidenemethyl]-pyrimidin-4-ylamine
  参考文献：
  名称：

  Van Calenbergh, Serge; De Bruyn, Andre; Schraml, Jan, Nucleosides & Nucleotides, 1997, vol. 16, # 3, p. 291 - 300

  摘要：

  DOI：

文献信息

• Pyrrolo\x9b2,3-d!pyrimidines and their use
  申请人：Novartis Finance Corp.

  公开号：US05869485A1

  公开（公告）日：1999-02-09

  The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumor diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I ##STR1## wherein n is from 0 to 5 and, when n is not 0, R is one or more substituents selected from halogen, alkyl, trifluoromethyl and alkoxy; and R.sub.1 and R.sub.2 are each independently of the other alkyl, or phenyl that is unsubstituted or substituted by halogen, trifluoromethyl, alkyl or by alkoxy, it also being possible for one of the two radicals R.sub.1 and R.sub.2 to be hydrogen, or R1 and R2 together form an alkylene chain having from 2 to 5 carbon atoms that is unsubstituted or substituted by alkyl; or salts thereof. Compounds of formula I inhibit protein kinases, for example the tyrosine protein kinase of the receptor for the epidermal growth factor, EGF.

  本发明涉及在治疗肿瘤疾病和其他增殖性疾病（例如银屑病）中使用下面提及的化合物，以及该类新颖化合物。这些化合物是公式I的化合物：##STR1##，其中n为0到5，当n不为0时，R为选自卤素、烷基、三氟甲基和烷氧基的一个或多个取代基；R.sub.1和R.sub.2各自独立地为烷基，或为未取代或被卤素、三氟甲基、烷基或烷氧基取代的苯基，两个自由基R.sub.1和R.sub.2中的一个也可以是氢，或者R1和R2共同形成一个有2到5个碳原子的未取代或被烷基取代的亚烷基链；或其盐。公式I的化合物可以抑制蛋白激酶，例如表皮生长因子（EGF）受体的酪氨酸蛋白激酶。
• Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
  申请人：Schering Corporation and Pharmacopeia, Inc.

  公开号：US20040209878A1

  公开（公告）日：2004-10-21

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的吡唑并[1,5-a]嘧啶类化合物，作为细胞周期依赖性激酶的抑制剂，以及制备这类化合物的方法、含有一种或多种这类化合物的药物组合物、制备含有一种或多种这类化合物的药物配方的方法，以及使用这类化合物或药物组合物进行一种或多种与CDKs相关的疾病的治疗、预防、抑制或改善的方法。
• Substituted hydroxyalkyl-azoles and their use as antimycotics
  申请人：Bayer Aktiengesellschaft

  公开号：US04879385A1

  公开（公告）日：1989-11-07

  The invention relates to substituted hydroxyalkylazoles defined herein by formula (I), which compounds are useful as antimycotic agents. Also included in the invention are compositions containing said compounds and methods for the use of said compounds and compositions. In addition, the invention includes methods for the manufacture of the compounds of formula (I).

  本发明涉及由式(I)所定义的取代羟基烷基唑化合物，该化合物可用作抗真菌剂。本发明还包括含有上述化合物的组合物以及使用上述化合物和组合物的方法。此外，本发明还涉及制备式(I)化合物的方法。
• Pyrazolopyrimidines as cyclin dependent kinase inhibitors
  申请人：Guzi J. Timothy

  公开号：US20070225270A1

  公开（公告）日：2007-09-27

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的嘧唑并[1,5-a]嘧啶化合物类作为细胞周期蛋白依赖性激酶的抑制剂，制备这种化合物的方法，含有一种或多种这种化合物的制药组合物，制备包含一种或多种这种化合物的制药制剂的方法，以及使用这种化合物或制药组合物治疗、预防、抑制或缓解与CDKs相关的一种或多种疾病的方法。
• Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
  申请人：Schering Corpoartion

  公开号：US07196078B2

  公开（公告）日：2007-03-27

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的吡唑并[1,5-a]嘧啶类化合物，作为细胞周期蛋白依赖性激酶的抑制剂，以及制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备包含一种或多种这种化合物的药物制剂的方法，以及使用这种化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。